Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Renalytix Plc (RENX) Share Price

Intraday
Historical

Price	6.85p on 14-11-2025 at 19:00:08
Change	0.00p 0%
Buy	6.90p
Sell	6.80p

Last Trade:	Buy 869.00 at 6.90p
Day's Volume:	98,310
Last Close:	6.85p
Open:	6.85p
ISIN:	GB00BYWL4Y04

Day's Range	6.85p - 6.85p
52wk Range:	5.75p - 12.50p
Market Capitalisation:	£29.94m
VWAP:	6.840204p
Shares in Issue:	437.02m

Sector: Health Care and Related Services

Listed In: FTSE AIM All-Share,

Buy/Sell	Volume	Trade Prc	Trade Type	Trade Time
Renalytix Plc (RENX) Latest Trades
Buy*	869	6.90p	Ordinary	16:27:00 - 14-Nov-25
Sell*	10,184	6.835p	Ordinary	15:41:17 - 14-Nov-25
Sell*	38,549	6.837p	Ordinary	14:55:20 - 14-Nov-25
Sell*	3,423	6.835p	Ordinary	13:59:23 - 14-Nov-25
Buy*	30,000	6.85p	Ordinary	12:23:17 - 14-Nov-25
Sell*	3,537	6.808p	Ordinary	08:26:00 - 14-Nov-25
Buy*	6,672	6.85p	Ordinary	14:51:16 - 13-Nov-25
Buy*	31,029	6.90p	Ordinary	14:21:34 - 13-Nov-25
Buy*	2,000	6.90p	Ordinary	14:21:09 - 13-Nov-25
Sell*	28,485	6.83p	Ordinary	14:14:49 - 13-Nov-25

See more Renalytix Plc trades

Renalytix Plc (RENX) Share Price History
Time period: to
Date	Open	High	Low	Close	Volume
14th Nov 2025 (Fri)	6.85	6.85	6.85	6.85	98,310
13th Nov 2025 (Thu)	6.85	6.85	6.85	6.85	296,406
12th Nov 2025 (Wed)	7.50	7.50	6.85	6.85	812,590
11th Nov 2025 (Tue)	7.25	7.25	7.15	7.25	336,223
10th Nov 2025 (Mon)	7.15	7.25	7.00	7.25	582,674
7th Nov 2025 (Fri)	7.15	7.15	6.90	7.15	714,945
6th Nov 2025 (Thu)	7.25	7.15	6.75	7.15	2,796,075
5th Nov 2025 (Wed)	7.25	7.25	7.25	7.25	691,010
4th Nov 2025 (Tue)	7.25	7.25	6.75	7.25	4,873,246
3rd Nov 2025 (Mon)	8.25	7.38	7.38	7.38	5,403,577
31st Oct 2025 (Fri)	8.25	8.25	8.25	8.25	262,056
30th Oct 2025 (Thu)	8.25	8.25	8.25	8.25	787,434
29th Oct 2025 (Wed)	8.25	8.25	8.25	8.25	182,407
28th Oct 2025 (Tue)	8.25	8.25	8.00	8.25	624,743
27th Oct 2025 (Mon)	8.55	8.52	8.25	8.52	1,472,888
24th Oct 2025 (Fri)	8.25	8.65	8.25	8.40	973,312
23rd Oct 2025 (Thu)	8.25	8.25	8.25	8.25	1,631,313
22nd Oct 2025 (Wed)	8.75	8.75	8.25	8.25	1,254,932
21st Oct 2025 (Tue)	8.75	9.00	8.75	8.75	2,102,454
20th Oct 2025 (Mon)	9.25	9.25	8.75	8.75	1,262,238
17th Oct 2025 (Fri)	8.75	9.75	8.60	9.25	13,720,789
16th Oct 2025 (Thu)	8.75	8.75	8.50	8.65	1,612,707

See more Renalytix Plc price history

Date	Source	Headline
Renalytix Plc (RENX) Regulatory News
12th Nov 2025 7:00 am	RNS	Pivotal kidneyintelX.dkd data published
5th Nov 2025 4:02 pm	RNS	Holding(s) in Company
4th Nov 2025 6:05 pm	RNS	Publication of Annual Report & Notice of AGM
3rd Nov 2025 12:05 pm	RNS	Holding(s) in Company
3rd Nov 2025 7:00 am	RNS	Audited Full Year Fiscal 2025 Results
30th Oct 2025 4:58 pm	RNS	Holding(s) in Company
28th Oct 2025 4:04 pm	RNS	Holding(s) in Company
27th Oct 2025 7:00 am	RNS	Confirmation of receipt of £860k R&D tax credits
24th Oct 2025 10:12 am	RNS	Holding(s) in Company
23rd Oct 2025 9:09 am	RNS	Holding(s) in Company

See more Renalytix Plc regulatory news

Renalytix Plc (RENX) Share News

TRADING UPDATES: Celsius raises funds; Built Cybernetics acquisition

12th Nov 2025 15:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

IN BRIEF: Renalytix loss narrows as costs down amid fewer employees

3rd Nov 2025 12:20

Renalytix PLC - London-based diagnostics company - Pretax loss narrows to USD21.8 million in the financial year ended June 30, from USD45.5 million a year prior. Revenue climbs 30% to USD3.0 million from USD2.3 million, with the company citing revenue growth across all revenue streams, as well as additional integration with a large physician practice in New York and increased pharma services revenue from global pharma leaders. Administrative costs reduce by 40% to USD18.4 million from USD30.7 million. This was "driven by headcount and operations optimization, delisting from NASDAQ, and the regaining foreign private issuer status. While reorganisation and delisting costs were higher than anticipated, the resulting reduction has provided a lower, predictable cash burn profile." Looking ahead, Renalytix says it continued to strengthen its presence in its initial three target states of Florida, Texas and New York. The company expects to announce additional complimentary strategic agreements in the current financial year running til the end of June 2026. Read More

TRADING UPDATES: Light Science contract win; One Health sales jump

27th Oct 2025 15:45

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

IN BRIEF: Renalytix gets USD4 million balance sheet boost

10th Oct 2025 18:14

Renalytix PLC - London-based diagnostics company - Reports Heights Capital Ireland LLC-advised fund notifies company that approximately USD4 million of non-amortising senior convertible bonds will be capitalised. Says 31.7 million ordinary shares will be issued at 9.5 pence each, the same price as Renalytix's recent fundraise, which raised just over GBP1.0 million. Renalytix says the bond conversion will improve its debt-to-equity ratio and significantly improve its balance sheet, improving its net asset position by around USD4 million and saving up to USD1.4 million in accrued interest over the remaining life of the loan. Read More

AIM WINNERS & LOSERS: Sareum halts study over control group issues

10th Oct 2025 10:10

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday. Read More

See more Renalytix Plc news

FTSE 100 Latest

Value9,698.37

Change-109.31

Renalytix Plc (RENX) Share Price

Login to your account